View clinical trials related to Pregnancy Related.
Filter by:The purpose of this randomized controlled trial is to compare the effectiveness of epidural clonidine, dexmedetomidine, or fentanyl adjuncts for labor analgesia.
This project-also known as "Accountability for Care through Undoing Racism & Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase social support. ACURE4Moms is a pragmatic 4-arm cluster randomized controlled trial conducted with 40 prenatal practices across North Carolina. Practices will be randomly assigned to receive either: Arm 1 (Standard Care): North Carolina Medicaid Care management for high-risk pregnancies; Arm 2 (Data Accountability and Transparency): North Carolina Medicaid Care Management + Practice-level Data Accountability interventions; Arm 3 (Community-Based Doula Support): North Carolina Medicaid Care Management + Community-Based Doula support intervention for high-risk patients during pregnancy and postpartum; or Arm 4 (Data Accountability and Transparency + Community-Based Doula Support): North Carolina Medicaid Care Management + Both Arms 2 and 3 interventions. During each practice's 2-year intervention period, the practice will initiate prenatal care for ~750 patients (30,000 patients total), whose outcomes the investigators will follow and compare between arms until all these patients have reached 1-year post-delivery.
This study tests strategies for improving PrEP implementation in maternal and child health clinics using an interrupted time series.
The aim of this study was to compare maternal, clinical and ultrasound estimations of fetal weight in women with severe (BMI>35) and morbid (BMI>40) obesity and to determine the effect of maternal body mass index (BMI) on these estimations.
Anaemia is defined as the lack of functioning red blood cells (RBCs) that leads to a decrease in the ability to carry oxygen causing a lot of complications during life time. Iron deficiency anaemia is a main public health problem in all countries. Over 30% of the world's population had anaemia; 4.3%-20% and 30%-48% respectively in developed and developing countries are affected by iron deficiency anaemia. Globally, it is estimated that roughly 38% of pregnant females, 29% non-pregnant women, and 29% of all females of reproductive age are diagnosed to have anaemia . WHO suggested a standard daily dose of 30 to 60 mg of iron and 400 µg of folic acid supplements to prevent anaemia in pregnancy. This dose of iron and folic acid should be taken ideally before gestation with the earliest possible time and must be continued throughout the gestational period. During pregnancy it is important to take adequate nutrition which is essential for optimal growth of the foetus and decrease in the incidence of congenital anomalies. adequate dietary intake of proteins and energy is not enough for normal weight of the new-born, decrease in vitamins and minerals can adversely affect the weight of the new- born . The prevalence of neural tube defects, low-birth weights, small babies for gestational age and maternal anaemia can be reduced by adequate intake of iron and folic acid supplements during pregnancy. A lot of studies show the same positive results for the intake of multivitamins ,but iron and folic acid are the most important . A lot of studies show the importance of the relationship between iron and folic acid supplement or multivitamins intake and the socio-economic factors as age, level of education, residence, marital status, parity, economic status, prenatal circumstances. There are association between more intake of supplements during pregnancy and a higher socioeconomic levels , level of education and use of prenatal medical services in studies conducted in Finland . The detection of anaemia in pregnancy is based on the examination of haemoglobin (Hb) levels at the first antenatal care visit. If the haemoglobin level is <11.9%, the pregnant woman is declared anaemic and should be given supplements of 60 mg iron tablets and 0.5 mg folic acid. This supplement is taken regularly 1 tablet per day for 90 consecutive days. If the haemoglobin level is still <11.9%, then the administration of iron tablets is continued. However, in practice, not all pregnant women take tablets regularly. This could be due to inadequate knowledge about the importance of iron tablets for pregnancy.
This study will be conducted to determine the effect of circuit weight training on calcium level and physical fitness in pregnant
Mother-to-child transmission (MTCT) is still the main transmission route of HBV in high-endemic areas, such as China, sub-Saharan Africa, etc. Some infants born of mothers with high HBV DNA load (≥2×10^5 IU/ml) are still infected with HBV even if these infants receive the combined immunization on time. Therefore, guidelines including AASLD and EASL recommend that pregnant women with high HBV DNA load should take antiviral drugs (tenofovir disoproxil fumarate or telbivudine) to reduce MTCT of HBV from gestation 24-28 weeks. However, side effects of TDF on infants are reported. For example, neutropenia and the decrease of bone mineral density are found in early age infants who are ever exposed to TDF during their fetal life. Tenofovir alafenamide (TAF), a new prodrug of tenofovir (TFV), has a higher antiviral potency, a higher peripheral blood mononuclear cell (PBMC) intracellular tenofovir diphosphate (TFV pp) level and a lower plasma TFV concentration. As the successor of TDF, the dose of TAF that is took orally every day is approximately 1/10 of TDF. TAF has a much lower risk of kidney toxicity and has almost no effect on the bone mineral density. TAF has been approved and recommended as the first-line drug to treat patients with chronic hepatitis B (CHB) by AASLD, EASL, etc. However, there are relatively few data of TAF on pregnancies with high HBV DNA load. It is urgently to clarify the safety and efficacy of TAF on interrupting MTCT of HBV in pregnancies with high HBV DNA load. In the present study, the investigators enroll middle/late pregnancies with high HBV DNA load(≥2×10^5 IU/ml). The participants are randomly divided into two groups. Then the participants are treated with TAF or TDF respectively. All enrolled participants are followed-up for 2 years. Objectives of the present study are as follows: A. To clarify safety and efficacy of TAF on interrupting MTCT of HBV in middle/late pregnancies with high HBV DNA load. B. To clarify effects of TAF on obstetric complications in middle/late pregnancies with CHB. C. To clarify effects of TAF on birth defects of infants born in mothers with CHB. D. To clarify the change of virology and biochemistry indexes in women with CHB during pregnancy and postpartum. E. To clarify effects of TAF treatment on participants. F. To clarify growth parameters of the infants exposed to TAF during their fetal life. G. To clarify the pharmacokinetics of TAF in pregnant populations.
This is a retrospective controlled survey study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. The study will compare migraine and pregnancy-related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group). Nerivio group participants will be recruited from Theranica's user base. Control group participants will be recruited by health care providers, including headache specialists and OBGYNs (study co-investigators). The study is based on an e-Survey including an e-eligibility questionnaire, an e-ICF ande-Questionnaire. Participants will be compensated for their time.
The effect of exposure to an informative video about amniocentesis before the procedure on maternal anxiety
For every case of maternal death, many more women experience life-threatening complications during pregnancy and childbirth. Yet, severe maternal morbidity (SMM) cases are often overlooked post-delivery. Women have reported that roughly 15% of SMM cases first occurred in the six weeks following delivery. The underlying factors associated with these morbidities are likely different than those occurring antenatally and at the time of delivery. Further research is required to elucidate the exact burden of SMM in the postpartum period in British Columbia (BC).